

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Vigonvita Life Sciences Co., Ltd.

蘇州旺山旺水生物醫藥股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2630)

SUPPLEMENTAL ANNOUNCEMENT ON ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025

Reference is made to the annual results of Vigonvita Life Sciences Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) for the year ended December 31, 2025 published on March 31, 2026 (the “**Annual Results**”) in relation to the use of proceeds from the Global Offering. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Annual Results.

In January 2026, the Group subscribed two unlisted market funds, both are independent third parties, amounted to HK\$35,124,000 and HK\$16,000,000, respectively. The subscription of HK\$35,124,000 (equivalent to RMB31,549,000) (the “**First Subscription**”) was funded by its own funds. However, the subscription of HK\$16,000,000 (equivalent to RMB14,423,000) (the “**Second Subscription**”) was inadvertently funded using the net proceeds from the Global Offering (the “**IPO Proceeds**”).

The Board (the “**Board**”) of the Directors (“**Director(s)**”) of the Company hereby explained that the inadvertent use of the IPO Proceeds was a result of oversight by the finance department of the Company rather than any intentional misuse:

- (i) at the time of the Second Subscription, the finance department of the Company failed to notice that the Company’s own funds in the relevant account were insufficient to cover the full subscription amount; and
- (ii) as disclosed in the prospectus of the Company dated October 28, 2025 (the “**Prospectus**”), “To the extent that the net proceeds from the Global Offering are not immediately applied to the above purposes and to the extent permitted by applicable law and regulations, we will only deposit the net proceeds in short-term interest-bearing accounts at licensed commercial banks and/or other authorized financial institutions.”, the finance department of the Company mistakenly believed that the subscription of the unlisted market fund fell within the scope of such permitted use.

Upon discovery of the inadvertent use of the IPO Proceeds, the Company has been in active discussions of the redemption. As of the date of this announcement, the Board confirms that the Second Subscription has been redeemed.

The Board deeply regrets the inadvertent use of the IPO Proceeds and confirms that the Company has implemented the following remedial actions in order to prevent similar incidents from occurring in the future:

- (i) the Company's legal advisers will provide a training session to its finance and accounting personnel, responsible staff, and senior management to strengthen and reinforce their understanding of (a) inside information requirements under Part XIVA of the Securities and Futures Ordinance (Cap. 571); and (b) discloseable transaction requirements under Chapter 14 of the Listing Rules;
- (ii) the Company will arrange regular quarterly trainings for its finance and accounting personnel to enhance their understanding of Listing Rules and the various disclosure obligations. These trainings will also cover topics such as risk management methodologies and internal protocols to report, approve and record transactions. Further, members of the Company's senior management will receive training every six months, while the Directors will have annual training sessions;
- (iii) the Company has implemented a new protocol and set up a mechanism in its Office Automation (the "OA") system whereby, prior to each transaction involving an amount of RMB2,000,000 or more, the relevant department/officers' application in OA system will be automatically routed to the finance department of the Company for approval. The finance department of the Company will check and make sure that the Company's own funds are sufficient to cover the transaction amount before proceeding with the transaction and further ensure that the IPO Proceeds will be used in accordance with the intended purposes as disclosed in the Prospectus; and
- (iv) prior to each transaction relating to purchase of wealth management products, the Company will consult with its compliance advisor, Somerley Capital Limited, and the joint company secretaries in advance going forward.

The Board further confirms that all IPO Proceeds will ultimately be used in accordance with the intended purposes as set out in the Prospectus and the incident of the inadvertent use of the IPO Proceeds has been disclosed in the annual report for the year ended December 31, 2025 published by the Company on April 30, 2026.

Further, the Company has confirmed with each of the fund managers of the First Subscription and Second Subscription that they are independent of each other and are not associates of each other, nor are they under the common control. Accordingly, the First Subscription and Second Subscription are not required to be aggregated for the purpose of size tests under Chapter 14 of the Listing Rules. As the highest applicable percentage ratio in relation to the First Subscription and Second Subscription and relevant subsequent redemption is less than 5%, none of such transaction constitutes a discloseable transaction.

The supplemental information contained in this announcement does not affect other information contained in the Annual Results. Save as disclosed above, all other information in the Annual Results remains unchanged.

By order of the Board
Vigonvita Life Sciences Co., Ltd.
Dr. Tian Guanghui
*Chairman of the Board, Executive Director,
Chief Executive Officer and General Manager*

Hong Kong, June 1, 2026

As at the date of this announcement, the Board comprises Dr. Tian Guanghui and Dr. Hu Tianwen as executive Directors, Mr. Liu Haoxuan as non-executive Director, and Dr. Ju Dianwen, Ms. Cao Xinwen and Dr. Xu Hongxi as independent non-executive Directors.